id
stringlengths 7
11
| context
stringlengths 24
527
| is_mult_event
bool 2
classes | annotations
list |
|---|---|---|---|
2796025_2 | This panic anxiety was not relieved by taking etizolam and flunitrazepam again, but subsided rapidly by the re-administration of mianserin 30 mg/day, and because of that the depressive symptom also disappeared. | true | [
{
"events": [
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"subsided\"]], \"start\": [[84]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"etizolam and flunitrazepam\", \"mianserin 30 mg/day\"]], \"start\": [[46, 129]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"panic anxiety\"], [\"depressive symptom\"]], \"start\": [[5], [174]], \"entity_id\": [\"T6\", \"T13\"]}, \"Drug\": {\"text\": [[\"flunitrazepam\"], [\"etizolam\"], [\"mianserin\"]], \"start\": [[59], [46], [129]], \"entity_id\": [\"T7\", \"T8\", \"T9\"]}, \"Dosage\": {\"text\": [[\"30 mg/day\"]], \"start\": [[139]], \"entity_id\": [\"T10\"]}, \"Combination\": [{\"event_id\": \"E1\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[55]], \"entity_id\": [\"T3\"]}, \"Drug\": {\"text\": [[\"etizolam\"], [\"flunitrazepam\"], [\"mianserin\"]], \"start\": [[46], [59], [129]], \"entity_id\": [\"T8\", \"T7\", \"T9\"]}}]}, \"Effect\": {\"text\": [[\"because of that the depressive symptom also disappeared\"]], \"start\": [[154]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
3101617_2 | When co-trimoxazole was stopped the red cell aplasia resolved. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"stopped\"]], \"start\": [[24]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"co-trimoxazole\"]], \"start\": [[5]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"co-trimoxazole\"]], \"start\": [[5]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"red cell aplasia resolved\"]], \"start\": [[36]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
10546851_1 | Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"co-administered\"]], \"start\": [[45]], \"entity_id\": [\"T11\"]}, \"Subject\": {\"text\": [[\"HIV-positive patients\"]], \"start\": [[64]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"Interaction of sildenafil and indinavir\"]], \"start\": [[0]], \"entity_id\": [\"T10\"], \"Disorder\": {\"text\": [[\"HIV-positive\"]], \"start\": [[64]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"sildenafil\"], [\"indinavir\"]], \"start\": [[15], [30]], \"entity_id\": [\"T13\", \"T14\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"Interaction\"]], \"start\": [[0]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"sildenafil\"], [\"indinavir\"]], \"start\": [[15], [30]], \"entity_id\": [\"T13\", \"T14\"]}}]}}"
}
]
}
] |
4095247_1 | Cerebral and ocular toxicity induced by desferrioxamine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[29]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Cerebral and ocular toxicity\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"desferrioxamine\"]], \"start\": [[40]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"desferrioxamine\"]], \"start\": [[40]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
7397053_1 | A patient developed papilloedema and hepatic dysfunction while being treated with perhexiline maleate. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"while\"]], \"start\": [[57]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"perhexiline maleate\"]], \"start\": [[82]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"perhexiline maleate\"]], \"start\": [[82]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"A patient\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"papilloedema and hepatic dysfunction\"]], \"start\": [[20]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
11868077_2 | We describe a case of subcutaneous metastasis along the needle track after percutaneous ethanol injection (PEI) for treatment of hepatocellular carcinoma. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[69]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"subcutaneous metastasis\"]], \"start\": [[22]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"percutaneous ethanol injection (PEI)\"]], \"start\": [[75]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"ethanol\"]], \"start\": [[88]], \"entity_id\": [\"T8\"]}, \"Route\": {\"text\": [[\"injection\"]], \"start\": [[96]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"hepatocellular carcinoma\"]], \"start\": [[129]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"a case\"]], \"start\": [[12]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
17420198_5 | He developed episodic movements possibly consistent with EPS secondary to aripiprazole usage. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[3]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"episodic movements possibly consistent with EPS\"]], \"start\": [[13]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"secondary to aripiprazole usage\"]], \"start\": [[61]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"aripiprazole\"]], \"start\": [[74]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
15133245_3 | Recently, it has been reported that terfenadine and astemizole, which have antiallergic actions similar to those of oxatomide, show side effects on the cardiovascular system, such as QT prolongation, ventricular arrhythmia and cardiac arrest. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"show\"]], \"start\": [[127]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"terfenadine and astemizole\"]], \"start\": [[36]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"terfenadine\"], [\"astemizole\"]], \"start\": [[36], [52]], \"entity_id\": [\"T11\", \"T12\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[48]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"terfenadine\"], [\"astemizole\"]], \"start\": [[36], [52]], \"entity_id\": [\"T11\", \"T12\"]}}]}, \"Effect\": {\"text\": [[\"side effects on the cardiovascular system, such as QT prolongation, ventricular arrhythmia and cardiac arrest\"]], \"start\": [[132]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
9476721_3 | We reported 3 patients who developed acute generalized dystonia and akinetic rigid syndrome following an initial therapy with d-penicillamine 125-500 mg daily. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[92]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"d-penicillamine 125-500 mg daily\"]], \"start\": [[126]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"d-penicillamine\"]], \"start\": [[126]], \"entity_id\": [\"T10\"]}, \"Dosage\": {\"text\": [[\"125-500 mg daily\"]], \"start\": [[142]], \"entity_id\": [\"T11\"]}}, \"Subject\": {\"text\": [[\"3 patients\"]], \"start\": [[12]], \"entity_id\": [\"T7\"], \"Population\": {\"text\": [[\"3\"]], \"start\": [[12]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"acute generalized dystonia and akinetic rigid syndrome\"]], \"start\": [[37]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
19579947_2 | Priapism associated with olanzapine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[9]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"Priapism\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"olanzapine\"]], \"start\": [[25]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"olanzapine\"]], \"start\": [[25]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
9883483_2 | Thus, an immunological mechanism might be involved in the mechanism of pirmenol-induced QT prolongation and T wave inversion on the electrocardiogram. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[80]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"pirmenol\"]], \"start\": [[71]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"pirmenol\"]], \"start\": [[71]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"QT prolongation and T wave inversion\"]], \"start\": [[88]], \"entity_id\": [\"T7\"]}, \"Speculated\": {\"text\": [[\"might be involved\"]], \"start\": [[33]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
16997047_1 | Five months after initiating mirtazapine therapy, she developed symptomatic hyponatremia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[54]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"symptomatic hyponatremia\"]], \"start\": [[64]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Five months after initiating mirtazapine\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Time_elapsed\": {\"text\": [[\"Five months\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"mirtazapine\"]], \"start\": [[29]], \"entity_id\": [\"T9\"]}}, \"Subject\": {\"text\": [[\"she\"]], \"start\": [[50]], \"entity_id\": [\"T6\"], \"Gender\": {\"text\": [[\"she\"]], \"start\": [[50]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
3797173_1 | Intravenous verapamil therapy in babies may cause apnea, hypotension, and bradycardia; continued episodes of atrial flutter in a child may cause sudden death; quinidine may be related to the death; children with "familial seizure disorders" may in fact have the long QT interval syndrome. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[44]], \"entity_id\": [\"T23\"]}, \"Treatment\": {\"text\": [[\"Intravenous verapamil\"]], \"start\": [[0]], \"entity_id\": [\"T20\"], \"Route\": {\"text\": [[\"Intravenous\"]], \"start\": [[0]], \"entity_id\": [\"T21\"]}, \"Drug\": {\"text\": [[\"verapamil\"]], \"start\": [[12]], \"entity_id\": [\"T22\"]}}, \"Subject\": {\"text\": [[\"babies\"]], \"start\": [[33]], \"entity_id\": [\"T18\"], \"Age\": {\"text\": [[\"babies\"]], \"start\": [[33]], \"entity_id\": [\"T19\"]}}, \"Effect\": {\"text\": [[\"apnea, hypotension, and bradycardia\"]], \"start\": [[50]], \"entity_id\": [\"T17\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[40]], \"entity_id\": [\"T29\"], \"value\": true}}"
},
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[176]], \"entity_id\": [\"T26\"]}, \"Treatment\": {\"text\": [[\"quinidine\"]], \"start\": [[159]], \"entity_id\": [\"T24\"], \"Drug\": {\"text\": [[\"quinidine\"]], \"start\": [[159]], \"entity_id\": [\"T25\"]}}, \"Effect\": {\"text\": [[\"death\"]], \"start\": [[191]], \"entity_id\": [\"T27\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[169]], \"entity_id\": [\"T28\"], \"value\": true}}"
}
]
}
] |
12796597_4 | The renal biopsy showed focal segmental glomerulosclerosis, which has only been previously reported in two cases of CML treated with IFNalpha. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"reported\"]], \"start\": [[91]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"The renal biopsy showed focal segmental glomerulosclerosis\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"two cases\"]], \"start\": [[103]], \"entity_id\": [\"T5\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[103]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"IFNalpha\"]], \"start\": [[133]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"CML\"]], \"start\": [[116]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"IFNalpha\"]], \"start\": [[133]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
6093724_2 | Sulindac (Clinoril), a nonsteroidal anti-inflammatory agent, has few reported neurologic toxic effects, all of which have been associated with systemic disease. | false | [
{
"events": [
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"reported\"]], \"start\": [[69]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"neurologic toxic effects\"]], \"start\": [[78]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Sulindac (Clinoril)\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Sulindac\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
19857154_7 | The second patient was a 32-year-old woman with HIV, anxiety disorder, and a history of intravenous drug abuse who developed increased sedation and mental confusion when an atazanavir-ritonavir-based antiretroviral regimen was added to her stable antianxiety drug regimen, which included quetiapine. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[115]], \"entity_id\": [\"T14\"]}, \"Subject\": {\"text\": [[\"a 32-year-old woman with HIV, anxiety disorder, and a history of intravenous drug abuse\"]], \"start\": [[23]], \"entity_id\": [\"T13\"], \"Age\": {\"text\": [[\"32-year-old\"]], \"start\": [[25]], \"entity_id\": [\"T17\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[37]], \"entity_id\": [\"T18\"]}, \"Disorder\": {\"text\": [[\"intravenous drug abuse\"]], \"start\": [[88]], \"entity_id\": [\"T21\"]}}, \"Effect\": {\"text\": [[\"increased sedation and mental confusion\"]], \"start\": [[125]], \"entity_id\": [\"T15\"]}, \"Treatment\": {\"text\": [[\"atazanavir-ritonavir-based antiretroviral regimen was added to her stable antianxiety drug regimen, which included quetiapine\"]], \"start\": [[173]], \"entity_id\": [\"T16\"], \"Drug\": {\"text\": [[\"quetiapine\"], [\"atazanavir\"], [\"ritonavir\"]], \"start\": [[288], [173], [184]], \"entity_id\": [\"T22\", \"T23\", \"T24\"]}, \"Disorder\": {\"text\": [[\"HIV\"], [\"anxiety disorder\"]], \"start\": [[48], [53]], \"entity_id\": [\"T26\", \"T27\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"added\"]], \"start\": [[227]], \"entity_id\": [\"T25\"]}, \"Drug\": {\"text\": [[\"ritonavir\"], [\"atazanavir\"], [\"quetiapine\"]], \"start\": [[184], [173], [288]], \"entity_id\": [\"T24\", \"T23\", \"T22\"]}}]}}"
}
]
}
] |
6860059_1 | Fulminant hepatitis associated with disulfiram. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[20]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"disulfiram\"]], \"start\": [[36]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"disulfiram\"]], \"start\": [[36]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"Fulminant hepatitis\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
3397227_1 | Anhedonic ejaculation with desipramine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[22]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Anhedonic ejaculation\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"desipramine\"]], \"start\": [[27]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"desipramine\"]], \"start\": [[27]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
9674820_1 | Serotonin syndrome induced by transitioning from phenelzine to venlafaxine: four patient reports. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[19]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Serotonin syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"phenelzine to venlafaxine\"]], \"start\": [[49]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"phenelzine\"], [\"venlafaxine\"]], \"start\": [[49], [63]], \"entity_id\": [\"T7\", \"T8\"]}}, \"Subject\": {\"text\": [[\"four patient\"]], \"start\": [[76]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
16960880_2 | Lower extremity arterial thrombosis following sonographically guided thrombin injection of a femoral pseudoaneurysm. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[36]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Lower extremity arterial thrombosis\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"thrombin injection of a femoral pseudoaneurysm\"]], \"start\": [[69]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"thrombin\"]], \"start\": [[69]], \"entity_id\": [\"T6\"]}, \"Route\": {\"text\": [[\"injection\"]], \"start\": [[78]], \"entity_id\": [\"T7\"]}, \"Disorder\": {\"text\": [[\"femoral pseudoaneurysm\"]], \"start\": [[93]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
8313300_6 | A severe form of exophthalmos resulting from lithium therapy has not been described in the literature. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"resulting\"]], \"start\": [[30]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"exophthalmos\"]], \"start\": [[17]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"lithium\"]], \"start\": [[45]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"lithium\"]], \"start\": [[45]], \"entity_id\": [\"T8\"]}}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[2]], \"entity_id\": [\"T9\"], \"value\": \"High\"}}"
}
]
}
] |
8604715_2 | No cases of renal acidosis, and only one case of nephrogenic diabetes insipidus, has been previously reported as a complication of foscarnet treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"reported\"]], \"start\": [[101]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"nephrogenic diabetes insipidus\"]], \"start\": [[49]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"foscarnet treatment\"]], \"start\": [[131]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"foscarnet\"]], \"start\": [[131]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
7919557_2 | Cough induced by quinapril with resolution after changing to fosinopril. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"resolution\"]], \"start\": [[32]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Cough\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"fosinopril\"]], \"start\": [[61]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"quinapril\"], [\"fosinopril\"]], \"start\": [[17], [61]], \"entity_id\": [\"T6\", \"T7\"]}}}"
}
]
}
] |
20298401_2 | INTRODUCTION: Although gefitinib used for the treatment of non-small-cell lung cancer is a well-known cause of interstitial lung disease (ILD), few case reports on erlotinib-induced ILD have been issued. | true | [
{
"events": [
{
"event_id": "E2",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[102]], \"entity_id\": [\"T16\"]}, \"Treatment\": {\"text\": [[\"gefitinib\"]], \"start\": [[23]], \"entity_id\": [\"T12\"], \"Disorder\": {\"text\": [[\"non-small-cell lung cancer\"]], \"start\": [[59]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"gefitinib\"]], \"start\": [[23]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"interstitial lung disease (ILD)\"]], \"start\": [[111]], \"entity_id\": [\"T15\"]}}"
},
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[174]], \"entity_id\": [\"T11\"]}, \"Treatment\": {\"text\": [[\"erlotinib\"]], \"start\": [[164]], \"entity_id\": [\"T17\"], \"Drug\": {\"text\": [[\"erlotinib\"]], \"start\": [[164]], \"entity_id\": [\"T18\"]}}, \"Effect\": {\"text\": [[\"ILD\"]], \"start\": [[182]], \"entity_id\": [\"T19\"]}}"
}
]
}
] |
17383767_4 | We report a case in which a potential drug interaction resulted in elevated phenytoin levels after initiation of erlotinib therapy in a patient who was receiving phenytoin. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"resulted in\"]], \"start\": [[55]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"a potential drug interaction\", \"initiation of erlotinib therapy\", \"receiving phenytoin\"]], \"start\": [[26, 99, 152]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"phenytoin\"], [\"erlotinib\"]], \"start\": [[162], [113]], \"entity_id\": [\"T16\", \"T17\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"interaction\"]], \"start\": [[43]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"erlotinib\"], [\"phenytoin\"]], \"start\": [[113], [162]], \"entity_id\": [\"T17\", \"T16\"]}}]}, \"Effect\": {\"text\": [[\"elevated phenytoin levels\"]], \"start\": [[67]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"a patient\"]], \"start\": [[134]], \"entity_id\": [\"T12\"]}, \"Speculated\": {\"text\": [[\"potential\"]], \"start\": [[28]], \"entity_id\": [\"T13\"], \"value\": true}}"
}
]
}
] |
18515982_1 | Anastrozole-associated sclerosing glomerulonephritis in a patient with breast cancer. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[12]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"a patient with breast cancer.\"]], \"start\": [[56]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Anastrozole\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Anastrozole\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"breast cancer\"]], \"start\": [[71]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"sclerosing glomerulonephritis\"]], \"start\": [[23]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
12324937_1 | BACKGROUND: Gemcitabine has mild renal toxicity, but cases of gemcitabine-associated hemolytic-uremic syndrome (HUS) have been reported. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[74]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"gemcitabine\"]], \"start\": [[62]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"gemcitabine\"]], \"start\": [[62]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"hemolytic-uremic syndrome (HUS)\"], [\"renal toxicity\"]], \"start\": [[85], [33]], \"entity_id\": [\"T11\", \"T14\"]}, \"Subject\": {\"text\": [[\"cases\"]], \"start\": [[53]], \"entity_id\": [\"T13\"]}, \"Severity\": {\"text\": [[\"mild\"]], \"start\": [[28]], \"entity_id\": [\"T15\"], \"value\": \"High\"}}"
}
]
}
] |
12460237_1 | Recurrent palmar-plantar erythrodysaesthesia following high-dose cytarabine treatment for acute lymphoblastic leukemia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treatment\"]], \"start\": [[76]], \"entity_id\": [\"T9\"]}, \"Effect\": {\"text\": [[\"palmar-plantar erythrodysaesthesia\"]], \"start\": [[10]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"high-dose cytarabine\"]], \"start\": [[55]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"cytarabine\"]], \"start\": [[65]], \"entity_id\": [\"T10\"]}, \"Dosage\": {\"text\": [[\"high-dose\"]], \"start\": [[55]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"acute lymphoblastic leukemia\"]], \"start\": [[90]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
12163813_1 | CONCLUSIONS: Peripheral administration of low-dose vasopressin for septic shock should be discouraged because of the risk of ischemic skin complications. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"risk\"]], \"start\": [[117]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"ischemic skin complications\"]], \"start\": [[125]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Peripheral administration of low-dose vasopressin\"]], \"start\": [[13]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"septic shock\"]], \"start\": [[67]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"vasopressin\"]], \"start\": [[51]], \"entity_id\": [\"T8\"]}, \"Dosage\": {\"text\": [[\"low-dose\"]], \"start\": [[42]], \"entity_id\": [\"T9\"]}, \"Route\": {\"text\": [[\"Peripheral administration\"]], \"start\": [[13]], \"entity_id\": [\"T10\"]}}, \"Speculated\": {\"text\": [[\"risk\"]], \"start\": [[117]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
21448111_3 | Many types of medicaments can cause akathisia as an adverse event of their use and they include: antipsychotics, antidepressants, antiemetics, antihistamines, and psychoactive substances. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"adverse event\"]], \"start\": [[52]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"antipsychotics, antidepressants, antiemetics, antihistamines, and psychoactive substances\"]], \"start\": [[97]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"antipsychotics\"], [\"antidepressants\"], [\"antiemetics\"], [\"antihistamines\"], [\"psychoactive substances.\"]], \"start\": [[97], [113], [130], [143], [163]], \"entity_id\": [\"T12\", \"T13\", \"T14\", \"T15\", \"T16\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[159]], \"entity_id\": [\"T17\"]}, \"Drug\": {\"text\": [[\"antipsychotics\"], [\"antidepressants\"], [\"antiemetics\"], [\"antihistamines\"], [\"psychoactive substances.\"]], \"start\": [[97], [113], [130], [143], [163]], \"entity_id\": [\"T12\", \"T13\", \"T14\", \"T15\", \"T16\"]}}]}, \"Effect\": {\"text\": [[\"akathisia\"]], \"start\": [[36]], \"entity_id\": [\"T11\"]}}"
}
]
}
] |
17039658_3 | We report the case of a 60-year-old woman who developed erythema and erosions in the axilla and groin while on PLD for breast cancer. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[46]], \"entity_id\": [\"T6\"]}, \"Subject\": {\"text\": [[\"a 60-year-old woman\", \"breast cancer\"]], \"start\": [[22, 119]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"60-year-old\"]], \"start\": [[24]], \"entity_id\": [\"T11\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[36]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"erythema\"], [\"erosions in the axilla and groin\"]], \"start\": [[56], [69]], \"entity_id\": [\"T7\", \"T8\"]}, \"Treatment\": {\"text\": [[\"PLD\"]], \"start\": [[111]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"PLD\"]], \"start\": [[111]], \"entity_id\": [\"T13\"]}, \"Disorder\": {\"text\": [[\"breast cancer\"]], \"start\": [[119]], \"entity_id\": [\"T14\"]}}}"
}
]
}
] |
18171260_2 | Serotonin syndrome has been reported with administration of linezolid and serotonin reuptake inhibitors. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"reported with\"]], \"start\": [[28]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"administration of linezolid and serotonin reuptake inhibitors\"]], \"start\": [[42]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"linezolid\"], [\"serotonin reuptake inhibitors\"]], \"start\": [[60], [74]], \"entity_id\": [\"T9\", \"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[70]], \"entity_id\": [\"T11\"]}, \"Drug\": {\"text\": [[\"linezolid\"], [\"serotonin reuptake inhibitors\"]], \"start\": [[60], [74]], \"entity_id\": [\"T9\", \"T10\"]}}]}, \"Effect\": {\"text\": [[\"Serotonin syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
6159523_6 | We suggest that the treatment of hypoglycaemia with 50% solution of dextrose is associated with a significant risk factor in those diabetic individuals who are either allergic or are receiving beta-adrenoreceptor blocking drugs. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[80]], \"entity_id\": [\"T14\"]}, \"Treatment\": {\"text\": [[\"50% solution of dextrose\"]], \"start\": [[52]], \"entity_id\": [\"T13\"], \"Disorder\": {\"text\": [[\"hypoglycaemia\"]], \"start\": [[33]], \"entity_id\": [\"T18\"]}, \"Drug\": {\"text\": [[\"dextrose\"]], \"start\": [[68]], \"entity_id\": [\"T12\"]}, \"Route\": {\"text\": [[\"50% solution\"]], \"start\": [[52]], \"entity_id\": [\"T19\"]}}, \"Subject\": {\"text\": [[\"diabetic individuals who are either allergic or are receiving beta-adrenoreceptor blocking drugs\"]], \"start\": [[131]], \"entity_id\": [\"T15\"], \"Disorder\": {\"text\": [[\"diabetic\"]], \"start\": [[131]], \"entity_id\": [\"T17\"]}}, \"Effect\": {\"text\": [[\"a significant risk factor\"]], \"start\": [[96]], \"entity_id\": [\"T16\"]}}"
}
]
}
] |
1509179_1 | A case of phenobarbital exacerbation of a preexisting maladaptive behavior partially suppressed by chlorpromazine and misinterpreted as chlorpromazine efficacy. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"exacerbation\"]], \"start\": [[24]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"phenobarbital\", \"partially suppressed by chlorpromazine\"]], \"start\": [[10, 75]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"phenobarbital\"], [\"chlorpromazine\"]], \"start\": [[10], [99]], \"entity_id\": [\"T8\", \"T9\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"suppressed\"]], \"start\": [[85]], \"entity_id\": [\"T3\"]}, \"Drug\": {\"text\": [[\"phenobarbital\"], [\"chlorpromazine\"]], \"start\": [[10], [99]], \"entity_id\": [\"T8\", \"T9\"]}}]}, \"Effect\": {\"text\": [[\"exacerbation of a preexisting maladaptive behavior\"]], \"start\": [[24]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"preexisting maladaptive behavior\"]], \"start\": [[42]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"preexisting maladaptive behavior\"]], \"start\": [[42]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
14632592_1 | Colchicine-induced myopathy in a teenager with familial Mediterranean fever. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[11]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"Colchicine\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"Mediterranean fever\"]], \"start\": [[56]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"Colchicine\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"myopathy\"]], \"start\": [[19]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a teenager with familial Mediterranean fever\"]], \"start\": [[31]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"teenager\"]], \"start\": [[33]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
18585545_4 | Levofloxacin-induced delirium with psychotic features. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[13]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"delirium with psychotic features\"]], \"start\": [[21]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Levofloxacin\"]], \"start\": [[0]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Levofloxacin\"]], \"start\": [[0]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
8007037_2 | Methemoglobinemia: an occupational hazard of phenylpropanolamine production. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"production\"]], \"start\": [[65]], \"entity_id\": [\"T5\"]}, \"Effect\": {\"text\": [[\"Methemoglobinemia\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"phenylpropanolamine\"]], \"start\": [[45]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"phenylpropanolamine\"]], \"start\": [[45]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
16498048_2 | Destructive thyrotoxicosis appeared 4-6 months after starting IFN-alpha, followed by Graves' hyperthyroidism within 8 to 11 months. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[47]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"Destructive thyrotoxicosis\", \"Graves' hyperthyroidism\"]], \"start\": [[0, 85]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"IFN-alpha\"]], \"start\": [[62]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"IFN-alpha\"]], \"start\": [[62]], \"entity_id\": [\"T8\"]}, \"Time_elapsed\": {\"text\": [[\"4-6 months\"]], \"start\": [[36]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
9220046_1 | CASE SUMMARIES: In each case, the patients were treated over 5 years with lovastatin and developed rhabdomyolysis that coincided with the completion of a prescribed regimen of a newer macrolide antibiotic. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[89]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[34]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"5 years with lovastatin\", \"a newer macrolide antibiotic\"]], \"start\": [[61, 176]], \"entity_id\": [\"T4\"], \"Duration\": {\"text\": [[\"5 years\"]], \"start\": [[61]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"lovastatin\"], [\"macrolide antibiotic\"]], \"start\": [[74], [184]], \"entity_id\": [\"T8\", \"T9\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"coincided\"]], \"start\": [[119]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"lovastatin\"], [\"macrolide antibiotic\"]], \"start\": [[74], [184]], \"entity_id\": [\"T8\", \"T9\"]}}]}, \"Effect\": {\"text\": [[\"rhabdomyolysis\"]], \"start\": [[99]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
11886466_1 | Thrombotic stroke associated with the use of porcine factor VIII in a patient with acquired haemophilia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[18]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"patient with acquired haemophilia\"]], \"start\": [[70]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"Thrombotic stroke\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"porcine factor VIII\"]], \"start\": [[45]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"porcine factor VIII\"]], \"start\": [[45]], \"entity_id\": [\"T12\"]}, \"Disorder\": {\"text\": [[\"acquired haemophilia\"]], \"start\": [[83]], \"entity_id\": [\"T13\"]}}}"
}
]
}
] |
16371793_2 | PURPOSE: The intravitreal application of triamcinolone acetonide as treatment of long-standing, therapy-resistant cystoid macular edema after penetrating keratoplasty is reported. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treatment\"]], \"start\": [[68]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"The intravitreal application of triamcinolone acetonide\"]], \"start\": [[9]], \"entity_id\": [\"T4\"], \"Route\": {\"text\": [[\"intravitreal\"]], \"start\": [[13]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"triamcinolone acetonide\"]], \"start\": [[41]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"cystoid macular edema\"]], \"start\": [[114]], \"entity_id\": [\"T9\"]}}}"
}
]
}
] |
23868369_8 | Patients receiving ciprofloxacin and digoxin should be monitored closely for the risk of digoxin toxicity. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"the risk\"]], \"start\": [[77]], \"entity_id\": [\"T11\"]}, \"Subject\": {\"text\": [[\"Patients\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"ciprofloxacin and digoxin\"]], \"start\": [[19]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"ciprofloxacin\"], [\"digoxin\"]], \"start\": [[19], [37]], \"entity_id\": [\"T12\", \"T13\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[33]], \"entity_id\": [\"T14\"]}, \"Drug\": {\"text\": [[\"digoxin\"], [\"ciprofloxacin\"]], \"start\": [[37], [19]], \"entity_id\": [\"T13\", \"T12\"]}}]}, \"Effect\": {\"text\": [[\"digoxin toxicity\"]], \"start\": [[89]], \"entity_id\": [\"T10\"]}, \"Speculated\": {\"text\": [[\"should\"]], \"start\": [[45]], \"entity_id\": [\"T9\"], \"value\": true}}"
}
]
}
] |
11443640_2 | To our knowledge this is the first report of pancytopenia due to MMI, where the usual hypoplasia found is replaced by massive plasmocytosis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due\"]], \"start\": [[58]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"pancytopenia\"]], \"start\": [[45]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"MMI\"]], \"start\": [[65]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"MMI\"]], \"start\": [[65]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
4082283_3 | The following is a report of 2 cases of rifampicin-induced renal insufficiency. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[51]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"rifampicin\"]], \"start\": [[40]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"rifampicin\"]], \"start\": [[40]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"renal insufficiency\"]], \"start\": [[59]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
8435665_2 | Fatal eosinophilia myalgia syndrome in a marrow transplant patient attributed to total parenteral nutrition with a solution containing tryptophan. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"attributed\"]], \"start\": [[67]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Fatal eosinophilia myalgia syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"marrow transplant patient\"]], \"start\": [[41]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"total parenteral nutrition with a solution containing tryptophan\"]], \"start\": [[81]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"tryptophan\"]], \"start\": [[135]], \"entity_id\": [\"T7\"]}, \"Route\": {\"text\": [[\"parenteral\"]], \"start\": [[87]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
14601701_4 | We describe a 43-year-old man who developed signs and symptoms of bilateral optic neuropathy during treatment with ethambutol. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[34]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"43-year-old man\"]], \"start\": [[14]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"43-year-old\"]], \"start\": [[14]], \"entity_id\": [\"T10\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[26]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"bilateral optic neuropathy\"]], \"start\": [[66]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"ethambutol\"]], \"start\": [[115]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"ethambutol\"]], \"start\": [[115]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
8445549_3 | The patient described in this paper was a 78-year-old diabetic man who developed oral lesions of PV following institution of glibenclamide therapy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[100]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"institution of glibenclamide\"]], \"start\": [[110]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"glibenclamide\"]], \"start\": [[125]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"diabetic\"]], \"start\": [[54]], \"entity_id\": [\"T11\"]}}, \"Subject\": {\"text\": [[\"The patient described in this paper was a 78-year-old diabetic man\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Age\": {\"text\": [[\"78-year-old\"]], \"start\": [[42]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[63]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"oral lesions of PV\"]], \"start\": [[81]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
16146480_2 | Since elevated cortisol levels in Cushing's disease poses a threat for pancreatitis, there is a possibility that patients with Cushing's disease might be more prone to acute pancreatitis following propofol administration. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[187]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"acute pancreatitis\"]], \"start\": [[168]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"propofol\"]], \"start\": [[197]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"propofol\"]], \"start\": [[197]], \"entity_id\": [\"T12\"]}, \"Disorder\": {\"text\": [[\"Cushing's disease\"]], \"start\": [[127]], \"entity_id\": [\"T13\"]}}, \"Subject\": {\"text\": [[\"patients with Cushing's disease\"]], \"start\": [[113]], \"entity_id\": [\"T6\"]}, \"Speculated\": {\"text\": [[\"might\"]], \"start\": [[145]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
9433539_3 | Ticlopidine is an oral antiplatelet agent frequently utilized in the treatment of cerebrovascular disease and is rarely associated with severe bone marrow suppression, typically aplastic anemia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[120]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"Ticlopidine is an oral antiplatelet agent\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"cerebrovascular disease\"]], \"start\": [[82]], \"entity_id\": [\"T5\"]}, \"Drug\": {\"text\": [[\"Ticlopidine\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}, \"Route\": {\"text\": [[\"oral\"]], \"start\": [[18]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"severe bone marrow suppression, typically aplastic anemia\"]], \"start\": [[136]], \"entity_id\": [\"T9\"]}, \"Speculated\": {\"text\": [[\"rarely\"]], \"start\": [[113]], \"entity_id\": [\"T7\"], \"value\": true}}"
}
]
}
] |
21715267_2 | Moxifloxacin and lomefloxacin are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treating\"]], \"start\": [[70]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"Moxifloxacin and lomefloxacin\", \"fluoroquinolone antibiotics\"]], \"start\": [[0, 34]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"Moxifloxacin\"], [\"lomefloxacin\"], [\"fluoroquinolone antibiotics\"]], \"start\": [[0], [17], [34]], \"entity_id\": [\"T11\", \"T12\", \"T13\"]}, \"Disorder\": {\"text\": [[\"urinary and respiratory tract infections\"]], \"start\": [[79]], \"entity_id\": [\"T14\"]}}}"
}
]
}
] |
9337441_14 | To our knowledge, this case report represents only the third description of laxative-induced TEN. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[85]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"laxative\"]], \"start\": [[76]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"laxative\"]], \"start\": [[76]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"TEN\"]], \"start\": [[93]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
21417793_2 | Prompted by the advent of potentially life-threatening neuromuscular symptoms following initiation of linezolid therapy in two patients receiving treatment with a serotonin reuptake inhibitor antidepressant, an evaluation was conducted to determine the incidence and characteristics of symptomatic serotonin toxicity among hospitalized patients receiving combined treatment with these medications. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[78]], \"entity_id\": [\"T17\"]}, \"Treatment\": {\"text\": [[\"linezolid\", \"with a serotonin reuptake inhibitor antidepressant\"]], \"start\": [[102, 156]], \"entity_id\": [\"T15\"], \"Drug\": {\"text\": [[\"serotonin reuptake inhibitor antidepressant\"], [\"linezolid\"]], \"start\": [[163], [102]], \"entity_id\": [\"T20\", \"T21\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"with\"]], \"start\": [[156]], \"entity_id\": [\"T22\"]}, \"Drug\": {\"text\": [[\"linezolid\"], [\"serotonin reuptake inhibitor antidepressant\"]], \"start\": [[102], [163]], \"entity_id\": [\"T21\", \"T20\"]}}]}, \"Effect\": {\"text\": [[\"life-threatening neuromuscular symptoms\"]], \"start\": [[38]], \"entity_id\": [\"T16\"]}, \"Subject\": {\"text\": [[\"two patients\"]], \"start\": [[123]], \"entity_id\": [\"T14\"], \"Population\": {\"text\": [[\"two\"]], \"start\": [[123]], \"entity_id\": [\"T18\"]}}, \"Severity\": {\"text\": [[\"life-threatening\"]], \"start\": [[38]], \"entity_id\": [\"T19\"], \"value\": \"High\"}}"
}
]
}
] |
15543388_2 | Celiac disease onset after pegylated interferon and ribavirin treatment of chronic hepatitis C. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"onset\"]], \"start\": [[15]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"pegylated interferon and ribavirin treatment of chronic hepatitis C\"]], \"start\": [[27]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"pegylated interferon\"], [\"ribavirin treatment\"]], \"start\": [[27], [52]], \"entity_id\": [\"T7\", \"T9\"]}, \"Disorder\": {\"text\": [[\"chronic hepatitis C\"]], \"start\": [[75]], \"entity_id\": [\"T10\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[48]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"pegylated interferon\"], [\"ribavirin treatment\"]], \"start\": [[27], [52]], \"entity_id\": [\"T7\", \"T9\"]}}]}, \"Effect\": {\"text\": [[\"Celiac disease\"]], \"start\": [[0]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
8244201_3 | Hyperkalaemia with renal tubular dysfunction by sulfamethoxazole-trimethoprim for Pneumocystis carinii pneumonia in patients with lymphoid malignancy. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"by\"]], \"start\": [[45]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"patients with lymphoid malignancy\"]], \"start\": [[116]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"lymphoid malignancy\"]], \"start\": [[130]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"Hyperkalaemia with renal tubular dysfunction\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"sulfamethoxazole-trimethoprim for Pneumocystis carinii pneumonia\"]], \"start\": [[48]], \"entity_id\": [\"T6\"], \"Disorder\": {\"text\": [[\"Pneumocystis carinii pneumonia\"]], \"start\": [[82]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"sulfamethoxazole-trimethoprim\"]], \"start\": [[48]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
19540093_2 | Following 7 days of tigecycline she developed severe abdominal pain and elevated pancreatic enzymes suggesting acute pancreatitis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[36]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"7 days of tigecycline\"]], \"start\": [[10]], \"entity_id\": [\"T7\"], \"Time_elapsed\": {\"text\": [[\"7 days\"]], \"start\": [[10]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"tigecycline\"]], \"start\": [[20]], \"entity_id\": [\"T11\"]}}, \"Effect\": {\"text\": [[\"abdominal pain and elevated pancreatic enzymes\"]], \"start\": [[53]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"she\"]], \"start\": [[32]], \"entity_id\": [\"T12\"]}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[46]], \"entity_id\": [\"T13\"], \"value\": \"High\"}}"
}
]
}
] |
11850606_4 | To treat hepatitis B, interferon alpha was administered until the proximal muscle weakness developed. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[91]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"interferon alpha\"]], \"start\": [[22]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"hepatitis B\"]], \"start\": [[9]], \"entity_id\": [\"T7\"]}, \"Drug\": {\"text\": [[\"interferon alpha\"]], \"start\": [[22]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"proximal muscle weakness\"]], \"start\": [[66]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
16882112_4 | We report a case of the serotonin syndrome during treatment with lithium and venlafaxine, an antidepressant with a dual selective re-uptake inhibition mechanism, and review the literature for similar cases. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[43]], \"entity_id\": [\"T10\"]}, \"Effect\": {\"text\": [[\"serotonin syndrome\"]], \"start\": [[24]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"lithium and venlafaxine\"]], \"start\": [[65]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"lithium\"], [\"venlafaxine\"]], \"start\": [[65], [77]], \"entity_id\": [\"T11\", \"T12\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[73]], \"entity_id\": [\"T13\"]}, \"Drug\": {\"text\": [[\"lithium\"], [\"venlafaxine\"]], \"start\": [[65], [77]], \"entity_id\": [\"T11\", \"T12\"]}}]}, \"Subject\": {\"text\": [[\"a case\"]], \"start\": [[10]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
19531695_13 | Supratherapeutic flecainide plasma concentrations may cause delirium. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[54]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"delirium\"]], \"start\": [[60]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Supratherapeutic flecainide plasma concentrations\"]], \"start\": [[0]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"flecainide\"]], \"start\": [[17]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
19499966_1 | At the end of his fifth cycle of sunitinib therapy, the patient complained of the development of abnormally large mammary glands associated with pain and peri-areolar erythema. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"development\"]], \"start\": [[82]], \"entity_id\": [\"T10\"]}, \"Treatment\": {\"text\": [[\"fifth cycle of sunitinib therapy\"]], \"start\": [[18]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"sunitinib\"]], \"start\": [[33]], \"entity_id\": [\"T11\"]}, \"Freq\": {\"text\": [[\"fifth cycle\"]], \"start\": [[18]], \"entity_id\": [\"T12\"]}}, \"Subject\": {\"text\": [[\"the patient\"]], \"start\": [[52]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"abnormally large mammary glands associated with pain and peri-areolar erythema\"]], \"start\": [[97]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
18644535_2 | This is a case report of possible association of methylphenidate and enuresis in an 11-year-old boy with attention deficit hyperactivity disorder. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"association\"]], \"start\": [[34]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"methylphenidate\"]], \"start\": [[49]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"methylphenidate\"]], \"start\": [[49]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"attention deficit hyperactivity disorder\"]], \"start\": [[105]], \"entity_id\": [\"T12\"]}}, \"Effect\": {\"text\": [[\"enuresis\"]], \"start\": [[69]], \"entity_id\": [\"T4\"]}, \"Subject\": {\"text\": [[\"an 11-year-old boy with attention deficit hyperactivity disorder\"]], \"start\": [[81]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"11-year-old\"]], \"start\": [[84]], \"entity_id\": [\"T7\"]}, \"Gender\": {\"text\": [[\"boy\"]], \"start\": [[96]], \"entity_id\": [\"T8\"]}}, \"Speculated\": {\"text\": [[\"possible\"]], \"start\": [[25]], \"entity_id\": [\"T10\"], \"value\": true}}"
}
]
}
] |
19331262_4 | This report describes a case of neuroleptic malignant syndrome due to risperidone in a child with Joubert syndrome. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due to\"]], \"start\": [[63]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"a child with Joubert syndrome\"]], \"start\": [[85]], \"entity_id\": [\"T6\"], \"Age\": {\"text\": [[\"child\"]], \"start\": [[87]], \"entity_id\": [\"T10\"]}}, \"Treatment\": {\"text\": [[\"risperidone\"]], \"start\": [[70]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"Joubert syndrome\"]], \"start\": [[98]], \"entity_id\": [\"T12\"]}, \"Drug\": {\"text\": [[\"risperidone\"]], \"start\": [[70]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"neuroleptic malignant syndrome\"]], \"start\": [[32]], \"entity_id\": [\"T9\"]}}"
}
]
}
] |
21045170_3 | A 47-year-old HIV-infected man with dilated cardiomyopathy and prolonged QT syndrome with an automatic implantable cardiovascular defibrillator device was prescribed subcutaneous enfuvirtide 90 mg twice daily as part of his antiretroviral regimen and oral extended-release niacin 500 mg/day for a high-density lipoprotein level of 8 mg/dL. After 1 week of concomitant therapy, the patient began experiencing extreme redness, edema, and swelling at the injection site that corresponded with the flushing sensation due to niacin. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"experiencing\"]], \"start\": [[395]], \"entity_id\": [\"T20\"]}, \"Subject\": {\"text\": [[\"A 47-year-old HIV-infected man with dilated cardiomyopathy and prolonged QT syndrome with an automatic implantable cardiovascular defibrillator device\"]], \"start\": [[0]], \"entity_id\": [\"T17\"], \"Disorder\": {\"text\": [[\"dilated cardiomyopathy\"], [\"prolonged QT syndrome\"]], \"start\": [[36], [63]], \"entity_id\": [\"T18\", \"T1\"]}, \"Age\": {\"text\": [[\"47-year-old\"]], \"start\": [[2]], \"entity_id\": [\"T22\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[27]], \"entity_id\": [\"T24\"]}}, \"Treatment\": {\"text\": [[\"subcutaneous enfuvirtide 90 mg twice daily as part of his antiretroviral regimen and oral extended-release niacin 500 mg/day for a high-density lipoprotein level of 8 mg/dL\"]], \"start\": [[166]], \"entity_id\": [\"T19\"], \"Disorder\": {\"text\": [[\"HIV-infected\"]], \"start\": [[14]], \"entity_id\": [\"T23\"]}, \"Dosage\": {\"text\": [[\"90 mg\"], [\"500 mg\"]], \"start\": [[191], [280]], \"entity_id\": [\"T25\", \"T31\"]}, \"Freq\": {\"text\": [[\"twice daily\"], [\"day\"]], \"start\": [[197], [287]], \"entity_id\": [\"T26\", \"T32\"]}, \"Drug\": {\"text\": [[\"enfuvirtide\"], [\"niacin\"]], \"start\": [[179], [273]], \"entity_id\": [\"T27\", \"T30\"]}, \"Route\": {\"text\": [[\"subcutaneous\"], [\"oral\"]], \"start\": [[166], [251]], \"entity_id\": [\"T28\", \"T29\"]}, \"Time_elapsed\": {\"text\": [[\"1 week\"]], \"start\": [[346]], \"entity_id\": [\"T3\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[247]], \"entity_id\": [\"T2\"]}, \"Drug\": {\"text\": [[\"niacin\"], [\"enfuvirtide\"]], \"start\": [[273], [179]], \"entity_id\": [\"T30\", \"T27\"]}}]}, \"Effect\": {\"text\": [[\"extreme redness, edema, and swelling at the injection site that corresponded with the flushing sensation due to niacin\"]], \"start\": [[408]], \"entity_id\": [\"T21\"]}}"
}
]
}
] |
7724306_1 | Acute INH neurotoxicity was not suspected on the first admission; however, when readmitted 4 weeks later with another seizure, the diagnosis of acute INH neurotoxicity was made. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"diagnosis\"]], \"start\": [[131]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"INH\"]], \"start\": [[150]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"INH\"]], \"start\": [[150]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"seizure\"], [\"acute INH neurotoxicity\"]], \"start\": [[118], [144]], \"entity_id\": [\"T8\", \"T9\"]}}"
}
]
}
] |
12066972_1 | Levofloxacin-induced toxic epidermal necrolysis in an elderly patient. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[13]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"an elderly patient.\"]], \"start\": [[51]], \"entity_id\": [\"T3\"], \"Age\": {\"text\": [[\"elderly\"]], \"start\": [[54]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"Levofloxacin\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Levofloxacin\"]], \"start\": [[0]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"toxic epidermal necrolysis\"]], \"start\": [[21]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
18079582_1 | The incidence of 5-fluorouracil (5-FU)-related cardiotoxicity seems to be dosage and schedule dependent. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[39]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"5-fluorouracil\", \"dosage\", \"schedule\"]], \"start\": [[17, 74, 85]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"5-fluorouracil (5-FU)\"]], \"start\": [[17]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"cardiotoxicity\"]], \"start\": [[47]], \"entity_id\": [\"T6\"]}, \"Speculated\": {\"text\": [[\"seems\"]], \"start\": [[62]], \"entity_id\": [\"T8\"], \"value\": true}}"
}
]
}
] |
19915794_3 | Torsades de Pointes induced by a combination of garenoxacin and disopyramide and other cytochrome P450, family 3, subfamily A polypeptide-4-influencing drugs during hypokalemia due to licorice. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[20]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Torsades de Pointes\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"a combination of garenoxacin and disopyramide and other cytochrome P450, family 3, subfamily A polypeptide-4-influencing drugs\"]], \"start\": [[31]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"garenoxacin\"], [\"disopyramide\"], [\"cytochrome P450, family 3, subfamily A polypeptide-4-influencing drugs\"]], \"start\": [[48], [64], [87]], \"entity_id\": [\"T7\", \"T8\", \"T9\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"combination\"]], \"start\": [[33]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"garenoxacin\"], [\"disopyramide\"], [\"cytochrome P450, family 3, subfamily A polypeptide-4-influencing drugs\"]], \"start\": [[48], [64], [87]], \"entity_id\": [\"T7\", \"T8\", \"T9\"]}}]}}"
}
]
}
] |
10981493_1 | Ataxia caused by propafenone has been reported to the pharmaceutical companies and drug monitoring agencies, but has not been well described or emphasized in the medical literature. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[7]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"propafenone\"]], \"start\": [[17]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"propafenone\"]], \"start\": [[17]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"Ataxia\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
7582710_2 | The first patient developed mild nitritoid symptoms and pain in a band-like distribution, corresponding to T10-T12 dermatomes, shortly after gold sodium thiomalate (GSTM) injection. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[18]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"gold sodium thiomalate (GSTM) injection\"]], \"start\": [[141]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"gold sodium thiomalate\"]], \"start\": [[141]], \"entity_id\": [\"T15\"]}, \"Route\": {\"text\": [[\"injection\"]], \"start\": [[171]], \"entity_id\": [\"T16\"]}}, \"Subject\": {\"text\": [[\"The first patient\"]], \"start\": [[0]], \"entity_id\": [\"T11\"]}, \"Effect\": {\"text\": [[\"mild nitritoid symptoms and pain in a band-like distribution\"]], \"start\": [[28]], \"entity_id\": [\"T13\"]}, \"Severity\": {\"text\": [[\"mild\"]], \"start\": [[28]], \"entity_id\": [\"T14\"], \"value\": \"Medium\"}}"
}
]
}
] |
9433539_1 | A case is reported of an elderly woman who developed febrile agranulocytosis several weeks after commencing ticlopidine but who had a favorable outcome after cessation of that drug and treatment with filgastrim. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[43]], \"entity_id\": [\"T7\"]}, \"Subject\": {\"text\": [[\"an elderly woman\"]], \"start\": [[22]], \"entity_id\": [\"T4\"], \"Age\": {\"text\": [[\"elderly\"]], \"start\": [[25]], \"entity_id\": [\"T5\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[33]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"febrile agranulocytosis\"]], \"start\": [[53]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"several weeks after commencing ticlopidine\"]], \"start\": [[77]], \"entity_id\": [\"T9\"], \"Time_elapsed\": {\"text\": [[\"several weeks\"]], \"start\": [[77]], \"entity_id\": [\"T10\"]}, \"Drug\": {\"text\": [[\"ticlopidine\"]], \"start\": [[108]], \"entity_id\": [\"T11\"]}}}"
},
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[152]], \"entity_id\": [\"T13\"]}, \"Subject\": {\"text\": [[\"an elderly woman\"]], \"start\": [[22]], \"entity_id\": [\"T4\"], \"Age\": {\"text\": [[\"elderly\"]], \"start\": [[25]], \"entity_id\": [\"T5\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[33]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"a favorable outcome\"]], \"start\": [[132]], \"entity_id\": [\"T12\"]}, \"Treatment\": {\"text\": [[\"cessation of that drug and treatment with filgastrim\"]], \"start\": [[158]], \"entity_id\": [\"T14\"], \"Disorder\": {\"text\": [[\"febrile agranulocytosis\"]], \"start\": [[53]], \"entity_id\": [\"T16\"]}, \"Drug\": {\"text\": [[\"filgastrim\"]], \"start\": [[200]], \"entity_id\": [\"T15\"]}}}"
}
]
}
] |
9824032_3 | Two 65-year-old white men with coronary heart disease, given niacin therapy for dyslipidemia for 5 months, developed intense dental and gingival pain that was associated with increases in dose and that was relieved with discontinuance of niacin treatment. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[107]], \"entity_id\": [\"T8\"]}, \"Treatment\": {\"text\": [[\"niacin therapy for dyslipidemia for 5 months\", \"increases in dose\"]], \"start\": [[61, 175]], \"entity_id\": [\"T7\"], \"Disorder\": {\"text\": [[\"dyslipidemia\"]], \"start\": [[80]], \"entity_id\": [\"T6\"]}, \"Drug\": {\"text\": [[\"niacin\"]], \"start\": [[61]], \"entity_id\": [\"T14\"]}, \"Dosage\": {\"text\": [[\"ncreases in dose\"]], \"start\": [[176]], \"entity_id\": [\"T15\"]}, \"Duration\": {\"text\": [[\"5 months\"]], \"start\": [[97]], \"entity_id\": [\"T16\"]}}, \"Effect\": {\"text\": [[\"intense dental and gingival pain\"]], \"start\": [[117]], \"entity_id\": [\"T9\"]}, \"Subject\": {\"text\": [[\"Two 65-year-old white men with coronary heart disease\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Disorder\": {\"text\": [[\"coronary heart disease\"]], \"start\": [[31]], \"entity_id\": [\"T5\"]}, \"Population\": {\"text\": [[\"Two\"]], \"start\": [[0]], \"entity_id\": [\"T10\"]}, \"Age\": {\"text\": [[\"65-year-old\"]], \"start\": [[4]], \"entity_id\": [\"T11\"]}, \"Race\": {\"text\": [[\"white\"]], \"start\": [[16]], \"entity_id\": [\"T12\"]}, \"Gender\": {\"text\": [[\"men\"]], \"start\": [[22]], \"entity_id\": [\"T13\"]}}}"
}
]
}
] |
3335488_2 | Two patients are described who developed testicular swelling and pain during treatment with desipramine. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[70]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"desipramine\"]], \"start\": [[92]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"desipramine\"]], \"start\": [[92]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"Two patients\"]], \"start\": [[0]], \"entity_id\": [\"T7\"], \"Population\": {\"text\": [[\"Two\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}}, \"Effect\": {\"text\": [[\"testicular swelling and pain\"]], \"start\": [[41]], \"entity_id\": [\"T8\"]}}"
}
]
}
] |
6635723_1 | Metabolic balance studies and rechallenge with hydrochlorothiazide were undertaken to investigate the mechanism of the thiazide-induced hyponatremia. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[128]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"hyponatremia\"]], \"start\": [[136]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"thiazide\"]], \"start\": [[119]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"hydrochlorothiazide\"], [\"thiazide\"]], \"start\": [[47], [119]], \"entity_id\": [\"T6\", \"T7\"]}}}"
}
]
}
] |
3926849_2 | Paradoxical pulmonary vasoconstriction induced by nitroglycerin in idiopathic pulmonary hypertension. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[39]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Paradoxical pulmonary vasoconstriction\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"nitroglycerin\"]], \"start\": [[50]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"nitroglycerin\"]], \"start\": [[50]], \"entity_id\": [\"T6\"]}, \"Disorder\": {\"text\": [[\"idiopathic pulmonary hypertension\"]], \"start\": [[67]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
12523465_1 | Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and altered mental status after zonisamide treatment was begun or its dosage increased. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[189]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"zonisamide\"]], \"start\": [[195]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"zonisamide\"]], \"start\": [[195]], \"entity_id\": [\"T8\"]}}, \"Effect\": {\"text\": [[\"complex visual hallucinations and altered mental status\"]], \"start\": [[133]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
17675030_2 | Clinical profile of oxcarbazepine-related angioneurotic edema: case report and review. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"related\"]], \"start\": [[34]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"oxcarbazepine\"]], \"start\": [[20]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"oxcarbazepine\"]], \"start\": [[20]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"angioneurotic edema\"]], \"start\": [[42]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"case\"]], \"start\": [[63]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
11788010_1 | Extra caution should be taken in using octreotide or its long-acting analog in patients otherwise predisposed to intrahepatic bile stasis. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"predisposed\"]], \"start\": [[98]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"octreotide or its long-acting analog\"]], \"start\": [[39]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"octreotide\"], [\"long-acting analog\"]], \"start\": [[39], [57]], \"entity_id\": [\"T7\", \"T8\"]}}, \"Effect\": {\"text\": [[\"intrahepatic bile stasis\"]], \"start\": [[113]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[79]], \"entity_id\": [\"T4\"]}}"
}
]
}
] |
8253700_1 | BACKGROUND: Fluoxetine, a highly specific serotonin reuptake inhibitor, has been reported to cause sexual dysfunction in a minority of patients. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"cause\"]], \"start\": [[93]], \"entity_id\": [\"T3\"]}, \"Effect\": {\"text\": [[\"sexual dysfunction\"]], \"start\": [[99]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Fluoxetine\"]], \"start\": [[12]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Fluoxetine\"]], \"start\": [[12]], \"entity_id\": [\"T6\"]}}, \"Subject\": {\"text\": [[\"minority of patients\"]], \"start\": [[123]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
18362995_4 | We report a 45-year-old Chinese man with CML and chronic hepatitis B virus infection, on imatinib treatment, presenting with herpetic rash and acute liver failure. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"presenting\"]], \"start\": [[109]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"a 45-year-old Chinese man with CML and chronic hepatitis B virus infection\"]], \"start\": [[10]], \"entity_id\": [\"T5\"], \"Age\": {\"text\": [[\"45-year-old\"]], \"start\": [[12]], \"entity_id\": [\"T9\"]}, \"Race\": {\"text\": [[\"Chinese\"]], \"start\": [[24]], \"entity_id\": [\"T10\"]}, \"Gender\": {\"text\": [[\"man\"]], \"start\": [[32]], \"entity_id\": [\"T11\"]}}, \"Treatment\": {\"text\": [[\"on imatinib treatment\"]], \"start\": [[86]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"imatinib\"]], \"start\": [[89]], \"entity_id\": [\"T13\"]}, \"Disorder\": {\"text\": [[\"CML and chronic hepatitis B\"]], \"start\": [[41]], \"entity_id\": [\"T14\"]}}, \"Effect\": {\"text\": [[\"herpetic rash and acute liver failure\"]], \"start\": [[125]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
3947272_4 | One patient had severe temporary weakness after an ampicillin sodium challenge. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"after\"]], \"start\": [[42]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"One patient\"]], \"start\": [[0]], \"entity_id\": [\"T3\"], \"Population\": {\"text\": [[\"One\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"temporary weakness\"]], \"start\": [[23]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"an ampicillin sodium challenge\"]], \"start\": [[48]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"ampicillin sodium\"]], \"start\": [[51]], \"entity_id\": [\"T8\"]}}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[16]], \"entity_id\": [\"T9\"], \"value\": \"High\"}}"
}
]
}
] |
11142491_1 | Acute myeloid leukemia and lung cancer occurring in a chronic lymphocytic leukemia patient treated with fludarabine and autologous peripheral blood stem-cell transplantation. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"occurring\"]], \"start\": [[39]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"Acute myeloid leukemia and lung cancer\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"a chronic lymphocytic leukemia patient\"]], \"start\": [[52]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"fludarabine and autologous peripheral blood stem-cell transplantation\"]], \"start\": [[104]], \"entity_id\": [\"T8\"], \"Drug\": {\"text\": [[\"fludarabine\"]], \"start\": [[104]], \"entity_id\": [\"T10\"]}, \"Disorder\": {\"text\": [[\"chronic lymphocytic leukemia\"]], \"start\": [[54]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
16960880_1 | Despite a very low complication rate, several severe arterial thrombotic events have been reported following thrombin injection of pseudoaneurysms. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"following\"]], \"start\": [[99]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"arterial thrombotic\"]], \"start\": [[53]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"thrombin injection\"]], \"start\": [[109]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"thrombin\"]], \"start\": [[109]], \"entity_id\": [\"T7\"]}, \"Route\": {\"text\": [[\"injection\"]], \"start\": [[118]], \"entity_id\": [\"T8\"]}, \"Disorder\": {\"text\": [[\"pseudoaneurysms\"]], \"start\": [[131]], \"entity_id\": [\"T9\"]}}, \"Severity\": {\"text\": [[\"severe\"]], \"start\": [[46]], \"entity_id\": [\"T10\"], \"value\": \"High\"}}"
}
]
}
] |
8396491_2 | The results clearly demonstrate that CPH82 was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"associated\"]], \"start\": [[47]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"CPH82\"]], \"start\": [[37]], \"entity_id\": [\"T6\"], \"Drug\": {\"text\": [[\"CPH82\"]], \"start\": [[37]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism\"]], \"start\": [[63]], \"entity_id\": [\"T7\"]}}"
}
]
}
] |
17060191_2 | Exposure of the fetus to indomethacin by administration of the drug to the mother may cause many side effects, including premature closure of the ductus arteriosus. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"side effects\"]], \"start\": [[97]], \"entity_id\": [\"T10\"]}, \"Subject\": {\"text\": [[\"fetus\"]], \"start\": [[16]], \"entity_id\": [\"T8\"], \"Age\": {\"text\": [[\"fetus\"]], \"start\": [[16]], \"entity_id\": [\"T12\"]}}, \"Treatment\": {\"text\": [[\"indomethacin\"]], \"start\": [[25]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"indomethacin\"]], \"start\": [[25]], \"entity_id\": [\"T13\"]}}, \"Effect\": {\"text\": [[\"premature closure of the ductus arteriosus\"]], \"start\": [[121]], \"entity_id\": [\"T11\"]}, \"Speculated\": {\"text\": [[\"may\"]], \"start\": [[82]], \"entity_id\": [\"T14\"], \"value\": true}}"
}
]
}
] |
19745701_3 | She was diagnosed with Epstein-Barr virus-associated polymorphic lymphoproliferative disorder (LPD) due to immunodeficiency caused by MTX administration. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"due\"]], \"start\": [[100]], \"entity_id\": [\"T8\"]}, \"Effect\": {\"text\": [[\"Epstein-Barr virus-associated polymorphic lymphoproliferative disorder (LPD)\"]], \"start\": [[23]], \"entity_id\": [\"T7\"]}, \"Treatment\": {\"text\": [[\"immunodeficiency caused by MTX administration\"]], \"start\": [[107]], \"entity_id\": [\"T9\"], \"Drug\": {\"text\": [[\"MTX\"]], \"start\": [[134]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"She\"]], \"start\": [[0]], \"entity_id\": [\"T11\"], \"Gender\": {\"text\": [[\"She\"]], \"start\": [[0]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |
17285101_1 | Pulmonary hypertension during lithium therapy: clinical case study. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"during\"]], \"start\": [[23]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"lithium therapy\"]], \"start\": [[30]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"lithium\"]], \"start\": [[30]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"Pulmonary hypertension\"]], \"start\": [[0]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
18682542_1 | CONCLUSIONS: Clinicians should be aware of this adverse reaction when facing similar complex neurologic symptoms in patients who are receiving the antibiotic treatment described here, especially vancomycin. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"adverse reaction\"]], \"start\": [[48]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"vancomycin\"]], \"start\": [[195]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"vancomycin\"]], \"start\": [[195]], \"entity_id\": [\"T7\"]}}, \"Subject\": {\"text\": [[\"patients\"]], \"start\": [[116]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"neurologic symptoms\"]], \"start\": [[93]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
19034138_3 | Corneal edema recurred when the administration of amantadine was resumed. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"when\"]], \"start\": [[23]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Corneal edema\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"the administration of amantadine was resumed\"]], \"start\": [[28]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"amantadine\"]], \"start\": [[50]], \"entity_id\": [\"T6\"]}}}"
}
]
}
] |
24661191_5 | Vitamin K1 caused skin rash possibly because of the distribution and metabolism characteristic of the drug in this patient. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"caused\"]], \"start\": [[11]], \"entity_id\": [\"T5\"]}, \"Treatment\": {\"text\": [[\"Vitamin K1\"]], \"start\": [[0]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"Vitamin K1\"]], \"start\": [[0]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"skin rash\"]], \"start\": [[18]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
15311565_1 | Initial treatment with heparin was substituted with thrombolysis, which resulted in clinical improvement and dissolution of right heart thrombus but was followed by fatal intracerebral haemorrhage. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"resulted\"]], \"start\": [[72]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"thrombolysis\"]], \"start\": [[52]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"thrombolysis\"]], \"start\": [[52]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"fatal intracerebral haemorrhage\"]], \"start\": [[165]], \"entity_id\": [\"T5\"]}, \"Severity\": {\"text\": [[\"fatal\"]], \"start\": [[165]], \"entity_id\": [\"T7\"], \"value\": \"High\"}}"
}
]
}
] |
14601701_3 | The most commonly recognized toxic effect of ethambutol is optic neuropathy, which generally is considered uncommon and reversible in medical literature. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"effect\"]], \"start\": [[35]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"ethambutol\"]], \"start\": [[45]], \"entity_id\": [\"T4\"], \"Drug\": {\"text\": [[\"ethambutol\"]], \"start\": [[45]], \"entity_id\": [\"T7\"]}}, \"Effect\": {\"text\": [[\"optic neuropathy\"]], \"start\": [[59]], \"entity_id\": [\"T5\"]}}"
}
]
}
] |
189279_1 | A case of congestive heart failure in a child with Wilms' tumor treated Adriamycin is presented and discussed. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"in\"]], \"start\": [[35]], \"entity_id\": [\"T6\"]}, \"Effect\": {\"text\": [[\"congestive heart failure\"]], \"start\": [[10]], \"entity_id\": [\"T3\"]}, \"Subject\": {\"text\": [[\"a child with Wilms' tumor\"]], \"start\": [[38]], \"entity_id\": [\"T4\"], \"Age\": {\"text\": [[\"child\"]], \"start\": [[40]], \"entity_id\": [\"T7\"]}}, \"Treatment\": {\"text\": [[\"Adriamycin\"]], \"start\": [[72]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"Adriamycin\"]], \"start\": [[72]], \"entity_id\": [\"T9\"]}, \"Disorder\": {\"text\": [[\"Wilms' tumor\"]], \"start\": [[51]], \"entity_id\": [\"T10\"]}}}"
}
]
}
] |
9494448_3 | BACKGROUND: Hypersensitivity reactions to cyclosporine are rare. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"to\"]], \"start\": [[39]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Hypersensitivity reactions\"]], \"start\": [[12]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"cyclosporine\"]], \"start\": [[42]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"cyclosporine\"]], \"start\": [[42]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
16484748_2 | This is the first case of TMP-SMX-induced hypersensitivity syndrome associated with the reactivation of a latent viral infection. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[34]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"TMP-SMX\"]], \"start\": [[26]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"TMP\"], [\"SMX\"]], \"start\": [[26], [30]], \"entity_id\": [\"T7\", \"T8\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"-\"]], \"start\": [[29]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"SMX\"], [\"TMP\"]], \"start\": [[30], [26]], \"entity_id\": [\"T8\", \"T7\"]}}]}, \"Effect\": {\"text\": [[\"hypersensitivity syndrome\", \"reactivation of a latent viral infection\"]], \"start\": [[42, 88]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"first case\"]], \"start\": [[12]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
24318743_15 | In addition, single-agent weekly AUC2-carboplatin appeared to be inactive by response criteria in a homogenously defined population of PROC. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"inactive\"]], \"start\": [[65]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"single-agent weekly AUC2-carboplatin\"]], \"start\": [[13]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"PROC\"]], \"start\": [[135]], \"entity_id\": [\"T8\"]}, \"Freq\": {\"text\": [[\"weekly\"]], \"start\": [[26]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"AUC2-carboplatin\"]], \"start\": [[33]], \"entity_id\": [\"T10\"]}}, \"Subject\": {\"text\": [[\"a homogenously defined population of PROC\"]], \"start\": [[98]], \"entity_id\": [\"T7\"]}, \"Negated\": {\"text\": [[\"inactive\"]], \"start\": [[65]], \"entity_id\": [\"T1\"], \"value\": true}}"
}
]
}
] |
18533420_1 | CONCLUSIONS: Intrathecal baclofen can impair sexual function and ejaculation in some patients. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"impair\"]], \"start\": [[38]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"Intrathecal baclofen\"]], \"start\": [[13]], \"entity_id\": [\"T3\"], \"Route\": {\"text\": [[\"Intrathecal\"]], \"start\": [[13]], \"entity_id\": [\"T9\"]}, \"Drug\": {\"text\": [[\"baclofen\"]], \"start\": [[25]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"impair sexual function and ejaculation\"]], \"start\": [[38]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"some patients\"]], \"start\": [[80]], \"entity_id\": [\"T6\"]}}"
}
]
}
] |
15671134_1 | A case of clozapine-induced tonic-clonic seizures managed with valproate: implications for clinical care. | true | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"induced\"]], \"start\": [[20]], \"entity_id\": [\"T4\"]}, \"Treatment\": {\"text\": [[\"clozapine\"]], \"start\": [[10]], \"entity_id\": [\"T3\"], \"Drug\": {\"text\": [[\"clozapine\"]], \"start\": [[10]], \"entity_id\": [\"T6\"]}}, \"Effect\": {\"text\": [[\"tonic-clonic seizures\"]], \"start\": [[28]], \"entity_id\": [\"T5\"]}, \"Subject\": {\"text\": [[\"A case\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}}"
},
{
"event_id": "E2",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E2\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"managed\"]], \"start\": [[50]], \"entity_id\": [\"T12\"]}, \"Subject\": {\"text\": [[\"A case\"]], \"start\": [[0]], \"entity_id\": [\"T9\"]}, \"Treatment\": {\"text\": [[\"valproate\"]], \"start\": [[63]], \"entity_id\": [\"T10\"], \"Drug\": {\"text\": [[\"valproate\"]], \"start\": [[63]], \"entity_id\": [\"T11\"]}, \"Disorder\": {\"text\": [[\"clozapine-induced tonic-clonic seizures\"]], \"start\": [[10]], \"entity_id\": [\"T8\"]}}}"
}
]
}
] |
10923593_2 | Serum sickness consists of a systemic reaction resulting from the formation of soluble circulating immunocomplexes after the introduction of a foreign substance into the body We studied a 38-year-old woman diagnosed with anxiety, depression and right sacroileitis who was treated with phenylbutazone, ranitidine, clomipramine and levomepromazine. | true | [
{
"events": [
{
"event_id": "E3",
"event_type": "Potential_therapeutic_event",
"event_data": "{\"event_id\": \"E3\", \"event_type\": \"Potential_therapeutic_event\", \"Trigger\": {\"text\": [[\"treated\"]], \"start\": [[272]], \"entity_id\": [\"T24\"]}, \"Subject\": {\"text\": [[\"a 38-year-old woman diagnosed with anxiety, depression and right sacroileitis\"]], \"start\": [[186]], \"entity_id\": [\"T13\"], \"Age\": {\"text\": [[\"38-year-old\"]], \"start\": [[188]], \"entity_id\": [\"T17\"]}, \"Gender\": {\"text\": [[\"woman\"]], \"start\": [[200]], \"entity_id\": [\"T18\"]}}, \"Treatment\": {\"text\": [[\"phenylbutazone, ranitidine, clomipramine and levomepromazin\"]], \"start\": [[285]], \"entity_id\": [\"T16\"], \"Drug\": {\"text\": [[\"phenylbutazone\"], [\"clomipramine\"], [\"levomepromazine\"], [\"ranitidine\"]], \"start\": [[285], [313], [330], [301]], \"entity_id\": [\"T19\", \"T20\", \"T21\", \"T22\"]}, \"Disorder\": {\"text\": [[\"anxiety, depression and right sacroileitis\"]], \"start\": [[221]], \"entity_id\": [\"T25\"]}, \"Combination\": [{\"event_id\": \"E2\", \"event_type\": \"Combination\", \"Trigger\": {\"text\": [[\"and\"]], \"start\": [[326]], \"entity_id\": [\"T23\"]}, \"Drug\": {\"text\": [[\"levomepromazine\"], [\"clomipramine\"], [\"ranitidine\"], [\"phenylbutazone\"]], \"start\": [[330], [313], [301], [285]], \"entity_id\": [\"T21\", \"T20\", \"T22\", \"T19\"]}}]}}"
}
]
}
] |
8276031_5 | The symptomatology of 18 other paediatric cases of naphthylimidazoline exposure reported to the Belgian National Poison Centre, is also discussed. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"symptomatology\"]], \"start\": [[4]], \"entity_id\": [\"T8\"]}, \"Subject\": {\"text\": [[\"18 other paediatric cases\"]], \"start\": [[22]], \"entity_id\": [\"T5\"], \"Population\": {\"text\": [[\"18\"]], \"start\": [[22]], \"entity_id\": [\"T9\"]}, \"Age\": {\"text\": [[\"paediatric\"]], \"start\": [[31]], \"entity_id\": [\"T10\"]}}, \"Effect\": {\"text\": [[\"naphthylimidazoline exposure\"]], \"start\": [[51]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"naphthylimidazoline\"]], \"start\": [[51]], \"entity_id\": [\"T7\"], \"Drug\": {\"text\": [[\"naphthylimidazoline\"]], \"start\": [[51]], \"entity_id\": [\"T11\"]}}}"
}
]
}
] |
85289_1 | Anterior spinal artery syndrome--a complication of cervical intrathecal phenol injection. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"complication\"]], \"start\": [[35]], \"entity_id\": [\"T4\"]}, \"Effect\": {\"text\": [[\"Anterior spinal artery syndrome\"]], \"start\": [[0]], \"entity_id\": [\"T3\"]}, \"Treatment\": {\"text\": [[\"cervical intrathecal phenol injection\"]], \"start\": [[51]], \"entity_id\": [\"T5\"], \"Drug\": {\"text\": [[\"phenol\"]], \"start\": [[72]], \"entity_id\": [\"T6\"]}, \"Route\": {\"text\": [[\"injection\"]], \"start\": [[79]], \"entity_id\": [\"T7\"]}}}"
}
]
}
] |
3677571_16 | Phenytoin was discontinued after admission; however, phenytoin 1 g i.v. was given for a tonic-clonic seizure two days after admission, after which swelling of the face and legs and pruritus developed. | false | [
{
"events": [
{
"event_id": "E1",
"event_type": "Adverse_event",
"event_data": "{\"event_id\": \"E1\", \"event_type\": \"Adverse_event\", \"Trigger\": {\"text\": [[\"developed\"]], \"start\": [[190]], \"entity_id\": [\"T7\"]}, \"Effect\": {\"text\": [[\"swelling of the face and legs and pruritus\"]], \"start\": [[147]], \"entity_id\": [\"T6\"]}, \"Treatment\": {\"text\": [[\"phenytoin 1 g i.v.\"]], \"start\": [[53]], \"entity_id\": [\"T5\"], \"Disorder\": {\"text\": [[\"a tonic-clonic seizure\"]], \"start\": [[86]], \"entity_id\": [\"T8\"]}, \"Drug\": {\"text\": [[\"phenytoin\"]], \"start\": [[53]], \"entity_id\": [\"T10\"]}, \"Dosage\": {\"text\": [[\"1 g\"]], \"start\": [[63]], \"entity_id\": [\"T11\"]}, \"Route\": {\"text\": [[\"i.v.\"]], \"start\": [[67]], \"entity_id\": [\"T12\"]}}}"
}
]
}
] |